Prospective Clinical Study of Postoperative Individualized Adjuvant Chemotherapy for Patients with Non-Small-Cell Lung Cancer Based on mRNA Expression of the Molecular Markers <i>RRM</i>1, <i>TUBB</i>3, and <i>ERCC</i>1

<div>Survival analysis of patients with low <i>RRM</i>1 expression and patients with high <i>RRM</i>1 expression in the paclitaxel-treated subgroup.</div>

Journal of Oncology

fig3

Figure 3

Figure 3: Prospective Clinical Study of Postoperative Individualized Adjuvant Chemotherapy for Patients with Non-Small-Cell Lung Cancer Based on mRNA Expression of the Molecular Markers <i>RRM</i>1, <i>TUBB</i>3, and <i>ERCC</i>1 

Figure 3 | Prospective Clinical Study of Postoperative Individualized Adjuvant Chemotherapy for Patients with Non-Small-Cell Lung Cancer Based on mRNA Expression of the Molecular Markers RRM1, TUBB3, and ERCC1 